نتایج جستجو برای: Pharmaceutical Policy

تعداد نتایج: 322894  

Journal: :international journal of management and business research 2015
h. olubunmi aderemi i. ayodele ojediran s. akinade adegbite o. olufunke olasanmi

this paper discussed the application of information and communication technology (ict) in pharmaceutical product marketing in nigeria. data for the study was obtained from 76 pharmaceutical firms in southwest nigeria which comprised of about 95% of the pharmaceutical companies that were into manufacturing of drugs in nigeria. the categories of firms surveyed include retail pharmacy, combination...

2015
Norman C Morrow

Across the world medicines are the ubiquitous technology in the diagnosis, treatment and prevention of disease. Pharmaceutical policy, as part of national health care policy, is concerned with the provision and use of medicines. Pharmacists are critical to the medicines management process, yet are often largely detached from policy development. Logically, they should inform Government policies ...

Journal: :iranian journal of pharmaceutical research 0
amir farshchi department of pharmacoeconomics and pharmaceutical administration, school of pharmacy, tehran university of medical sciences, tehran, iran. abbas kebriaeezadeh department of pharmacoeconomics and pharmaceutical administration, school of pharmacy, tehran university of medical sciences, tehran, iran. rassoul dinarvand department of pharmaceutics, school of pharmacy, tehran university of medical sciences, tehran 1417614411, iran.

information plays a vital role in effective management of any system. with the health management information system (hmis) specific information may be provide to support o the decision makers at various levels of the health system to assist evidence-based decision making. pharmaceutical distributor companies have reported their sales data to moh at monthly intervals. each company should report ...

2005
Robert Popovian Kathleen A. Johnson Michael B. Nichol Gordon Liu

ROBERT POPOVIAN, PHARM.D., MS., is Senior Medical Liaison, PJizer, Inc. At the time oj this study, he was Bristol-Myers Squibb Fellow, Department oj Pharmaceutical Economics and Policy, University oj Southern California School oj Pharmacy, Los Angeles, CA; KATHLEEN A. JOHNSON, PHARM.D., PH.D., is Associate proJessor oj Clinical Pharmacy and Pharmaceutical Economics and Policy, University oj Sou...

Journal: :international journal of health policy and management 2016
kyriakos souliotis elena alexopoulou manto papageorgiou anastasia politi panagiota litsa

background while there is currently no cure for multiple sclerosis (ms), treatment with biologic diseasemodifying drugs (bdmds) can reduce the impact of the condition on the lives of patients. in greece, the regulatory change in the distribution system of bdmds, limited their administration through the designated pharmacies of the national organization for healthcare services provision (eopyy) ...

2014
Christine Leopold Aukje K Mantel-Teeuwisse Sabine Vogler Silvia Valkova Kees de Joncheere Hubert GM Leufkens Anita K Wagner Dennis Ross-Degnan Richard Laing

OBJECTIVE To identify pharmaceutical policy changes during the economic recession in eight European countries and to determine whether policy measures resulted in lower sales of, and less expenditure on, pharmaceuticals. METHODS Information on pharmaceutical policy changes between 2008 and 2011 in eight European countries was obtained from publications and pharmaceutical policy databases. Dat...

This paper considers a two stages pharmaceutical supply chain (PSC) consisting of a pharmaceutical manufacturer (pharma-manufacturer) that supplies one type of pharmaceutical product to a pharma-retailer. The customer demand rate for the pharmaceutical product is dependent on the pharma-retailer’s current-inventory level. The pharma-retailer determines the order quantity ( ) value as decision v...

2014
Warren A Kaplan Veronika J Wirtz

Promoting generic medicines to increase access to essential medicines is relevant to achieve the Millennium Development Goal (MDGs) and post 2015 goals. There are several barriers to encouraging wider use of generic medicines in health systems, e.g. the widely-held perception that low price equals low quality and misalignment of provider and consumer incentives. Overcoming the complex barriers ...

Journal: :Folia Pharmacologica Japonica 2013

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید